CN103260703A - 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺 - Google Patents
作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺 Download PDFInfo
- Publication number
- CN103260703A CN103260703A CN201180061809XA CN201180061809A CN103260703A CN 103260703 A CN103260703 A CN 103260703A CN 201180061809X A CN201180061809X A CN 201180061809XA CN 201180061809 A CN201180061809 A CN 201180061809A CN 103260703 A CN103260703 A CN 103260703A
- Authority
- CN
- China
- Prior art keywords
- base
- chemical compound
- phenyl
- trifluoromethyl
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VNBVKYDZZMGCME-UHFFFAOYSA-N Cc1nc(cc(cc2)C(O)=O)c2[n]1-c(cc1F)ccc1F Chemical compound Cc1nc(cc(cc2)C(O)=O)c2[n]1-c(cc1F)ccc1F VNBVKYDZZMGCME-UHFFFAOYSA-N 0.000 description 1
- SXGARPXUHFOJFE-UHFFFAOYSA-N Cc1nc(cc(cc2)C(O)=O)c2[n]1-c1ccc(C(F)(F)F)cc1 Chemical compound Cc1nc(cc(cc2)C(O)=O)c2[n]1-c1ccc(C(F)(F)F)cc1 SXGARPXUHFOJFE-UHFFFAOYSA-N 0.000 description 1
- HLIJMHKQYSUDOJ-UHFFFAOYSA-N Cc1nc(cc(cc2)C(O)=O)c2[n]1-c1ccccc1 Chemical compound Cc1nc(cc(cc2)C(O)=O)c2[n]1-c1ccccc1 HLIJMHKQYSUDOJ-UHFFFAOYSA-N 0.000 description 1
- FXZIXZKGHOREOM-UHFFFAOYSA-N Cc1nc(cc(cc2)C(O)=O)c2[n]1CC(F)(F)F Chemical compound Cc1nc(cc(cc2)C(O)=O)c2[n]1CC(F)(F)F FXZIXZKGHOREOM-UHFFFAOYSA-N 0.000 description 1
- NBFLRIHCGANGEC-UHFFFAOYSA-N Cc1nc2cc(C(O)=O)ccc2[n]1C(CC1)CCC1(F)F Chemical compound Cc1nc2cc(C(O)=O)ccc2[n]1C(CC1)CCC1(F)F NBFLRIHCGANGEC-UHFFFAOYSA-N 0.000 description 1
- KULIEJJRZKUEQW-UHFFFAOYSA-N Cc1nc2cc(C(O)=O)ccc2[n]1CCC(F)(F)F Chemical compound Cc1nc2cc(C(O)=O)ccc2[n]1CCC(F)(F)F KULIEJJRZKUEQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40587610P | 2010-10-22 | 2010-10-22 | |
| US61/405876 | 2010-10-22 | ||
| PCT/US2011/057085 WO2012054716A1 (en) | 2010-10-22 | 2011-10-20 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103260703A true CN103260703A (zh) | 2013-08-21 |
Family
ID=44993878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180061809XA Pending CN103260703A (zh) | 2010-10-22 | 2011-10-20 | 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2629851A1 (es) |
| JP (1) | JP2013540159A (es) |
| KR (1) | KR20130142137A (es) |
| CN (1) | CN103260703A (es) |
| AR (1) | AR083542A1 (es) |
| AU (1) | AU2011316970A1 (es) |
| BR (1) | BR112013009858A2 (es) |
| CA (1) | CA2815350A1 (es) |
| IL (1) | IL225769A0 (es) |
| RU (1) | RU2013123275A (es) |
| TW (1) | TW201305136A (es) |
| WO (1) | WO2012054716A1 (es) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715613A (zh) * | 2016-03-31 | 2019-05-03 | 武田药品工业株式会社 | 杂环化合物 |
| CN109879797A (zh) * | 2019-01-10 | 2019-06-14 | 安徽昊帆生物有限公司 | N-苄基-四氢吡啶类化合物及其制备方法 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| AU2014239542A1 (en) * | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| US9624170B2 (en) | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| JP6653319B2 (ja) | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
| CA2981530A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| JP6832342B2 (ja) | 2016-03-31 | 2021-02-24 | 武田薬品工業株式会社 | 複素環化合物 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| CA3063440A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| CN111148746B (zh) | 2017-09-29 | 2022-08-05 | 武田药品工业株式会社 | 杂环化合物 |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101472910A (zh) * | 2006-05-18 | 2009-07-01 | 阿尔比里奥公司 | 用于治疗胃肠疾病的1-[(4-[苯甲酰基(甲基)氨基]-3-(苯基)丁基]氮杂环丁烷衍生物 |
| US20090269785A1 (en) * | 2008-04-25 | 2009-10-29 | Carsten Schubert | Crystal structure of monoacylglycerol lipase (mgll) |
| CN101663304A (zh) * | 2007-04-18 | 2010-03-03 | 赛诺菲-安万特 | 三唑并吡啶-甲酰胺和三唑并嘧啶-甲酰胺衍生物、它们的制备和它们的治疗应用 |
| WO2010124082A1 (en) * | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812037D0 (en) * | 1998-06-04 | 1998-07-29 | Pfizer Ltd | Piperidones |
| ES2422718T3 (es) * | 2009-04-02 | 2013-09-13 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de la autotaxina |
-
2011
- 2011-10-20 WO PCT/US2011/057085 patent/WO2012054716A1/en active Application Filing
- 2011-10-20 JP JP2013535086A patent/JP2013540159A/ja active Pending
- 2011-10-20 KR KR1020137012911A patent/KR20130142137A/ko not_active Application Discontinuation
- 2011-10-20 BR BR112013009858A patent/BR112013009858A2/pt not_active IP Right Cessation
- 2011-10-20 CN CN201180061809XA patent/CN103260703A/zh active Pending
- 2011-10-20 CA CA2815350A patent/CA2815350A1/en not_active Abandoned
- 2011-10-20 AU AU2011316970A patent/AU2011316970A1/en not_active Abandoned
- 2011-10-20 RU RU2013123275/04A patent/RU2013123275A/ru not_active Application Discontinuation
- 2011-10-20 EP EP11784828.3A patent/EP2629851A1/en not_active Withdrawn
- 2011-10-21 TW TW100138198A patent/TW201305136A/zh unknown
- 2011-10-24 AR ARP110103927A patent/AR083542A1/es not_active Application Discontinuation
-
2013
- 2013-04-15 IL IL225769A patent/IL225769A0/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101472910A (zh) * | 2006-05-18 | 2009-07-01 | 阿尔比里奥公司 | 用于治疗胃肠疾病的1-[(4-[苯甲酰基(甲基)氨基]-3-(苯基)丁基]氮杂环丁烷衍生物 |
| CN101663304A (zh) * | 2007-04-18 | 2010-03-03 | 赛诺菲-安万特 | 三唑并吡啶-甲酰胺和三唑并嘧啶-甲酰胺衍生物、它们的制备和它们的治疗应用 |
| US20090269785A1 (en) * | 2008-04-25 | 2009-10-29 | Carsten Schubert | Crystal structure of monoacylglycerol lipase (mgll) |
| WO2010124082A1 (en) * | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| 万志龙，等: "喹诺酮的合成与抗菌活性", 《国外医药抗生素分册》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715613A (zh) * | 2016-03-31 | 2019-05-03 | 武田药品工业株式会社 | 杂环化合物 |
| CN109715613B (zh) * | 2016-03-31 | 2021-07-30 | 武田药品工业株式会社 | 杂环化合物 |
| CN109879797A (zh) * | 2019-01-10 | 2019-06-14 | 安徽昊帆生物有限公司 | N-苄基-四氢吡啶类化合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201305136A (zh) | 2013-02-01 |
| EP2629851A1 (en) | 2013-08-28 |
| RU2013123275A (ru) | 2014-11-27 |
| IL225769A0 (en) | 2013-06-27 |
| WO2012054716A1 (en) | 2012-04-26 |
| KR20130142137A (ko) | 2013-12-27 |
| BR112013009858A2 (pt) | 2016-07-26 |
| JP2013540159A (ja) | 2013-10-31 |
| AU2011316970A1 (en) | 2013-05-09 |
| AR083542A1 (es) | 2013-03-06 |
| CA2815350A1 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103260703A (zh) | 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺 | |
| CN103261189B (zh) | 作为单酰基甘油脂肪酶抑制剂的氨基-吡咯烷-氮杂环丁烷二酰胺 | |
| EP2611774B1 (en) | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | |
| CN102458407B (zh) | 用作单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺 | |
| US8637498B2 (en) | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | |
| CN102548983B (zh) | 作为单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺 | |
| US8513423B2 (en) | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
| CN104936960A (zh) | 作为n型钙通道阻滞剂的吡咯并吡唑 | |
| CN106459030B (zh) | 取代托品烷衍生物 | |
| TW201313702A (zh) | 作為單醯基甘油脂酶抑制劑之側氧哌□－四氫吖唉醯胺及側氧二氮呯－四氫吖唉醯胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130821 |